Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight, an ophthalmic medical device company, has successfully closed its public offering of 2,053,571 shares of common stock at $56.00 per share. This includes the full exercise of underwriters' option to purchase an additional 267,857 shares, generating gross proceeds of $115 million. The offering was managed by BofA Securities, J.P. Morgan, and BTIG, with BofA Securities acting as the lead bookrunning manager. The automatic shelf registration statement and the final prospectus supplement were filed with the SEC on May 8, 2024. The proceeds are expected to support RxSight’s ongoing business activities and growth strategies.
RxSight, Inc., a medical device company specializing in vision care post cataract surgery, announced the pricing of its public offering of common stock. The company plans to sell 1,785,714 shares at $56.00 per share, expecting gross proceeds of approximately $100.0 million. The offering is set to close around May 13, 2024, with plans to utilize the funds for commercial expansion, product development, research, and general corporate purposes.
RxSight, Inc. announced a proposed public offering of $100 million of its common stock, with an additional 15% option for underwriters. The company plans to use the proceeds for commercial expansion, product development, research, and working capital. BofA Securities, J.P. Morgan, and BTIG are involved in the offering. An automatic shelf registration statement was filed with the SEC. The offering will be made through a prospectus supplement and accompanying prospectus.
RxSight, Inc. reported strong first quarter 2024 financial results, with a revenue of $29.5 million, a 69% increase compared to the first quarter of 2023. The company sold 20,218 Light Adjustable Lenses (LAL) and 66 Light Delivery Devices (LDD), showing significant growth in procedure volume and unit sales. Gross profit increased to $20.7 million, operating expenses rose to $31.4 million, and the company reported a net loss of $(9.1) million. However, adjusted net loss improved to $(4.4) million. Cash, cash equivalents, and short-term investments were $125.4 million as of March 31, 2024. RxSight raised its 2024 revenue guidance to $132.0 million to $137.0 million, gross margin guidance to 68% to 70%, and operating expense guidance to $126.0 million to $130.0 million.
RxSight, Inc., a medical device company specializing in customized vision after cataract surgery, will be presenting at the Bank of America Healthcare Conference on May 15, 2024. The presentation will be available for viewing online.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
